


USSN 10/800,241

CT-2774 NP

Amendments to the Claims

1. (currently amended) A compound of Formula (I)



or pharmaceutically acceptable salt ~~or solvate~~ thereof,

wherein

B is CH or N;

D is CH₂ or NH;

R¹ is selected from the group consisting of H, -CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy and N(C₁₋₄ alkyl)₂ optionally and independently substituted with 1 to 3 substituents selected from the group consisting of -CN, hydroxy, halo, C₁₋₄ haloalkyl and C₁₋₄ alkoxy;

R² is selected from the group consisting of H, halo, -CN, hydroxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, -NR⁴R⁶, -C₁₋₆alkylNR⁴R⁶, -C₁₋₆alkylOR⁶, CO₂R⁶, O₂CR⁶, COR⁶, CON⁴R⁶, NR⁴CO₂R⁶, NR⁴SO₂R⁶, NR⁴COR⁶, OCONR⁴R⁶ and NR⁴CONR⁵R⁶;

optionally and independently substituted with 1 to 3 substituents selected from the group consisting

USSN 10/800,241

CT-2774 NP

of -CN, hydroxy, halo, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, CO₂C₁₋₄ alkyl or phenyl; or

R² is morpholinyl, thiomorpholinyl, piperadiny, piperazinyl, phenyl, pyridyl, pyrimidinyl, triazinyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, pyrrolidinyl, dihydroimidazolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl and indazolyl, independently and optionally substituted with 1 to 4 substituents selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₄ alkoxy- C₁₋₄ alkyl, C₃₋₆ cycloalkyl, -OR⁴, halo, C₁₋₄ haloalkyl, -CN, SH, -S(O)₂R⁵, -COR⁴, -CO₂R⁴, -OC(O)R⁵, -N(COR⁴)₂, -NR⁴R⁷ and -CONR⁴R⁷, -NR⁴COR⁵, NR⁴SO₂R⁵, NR⁴CONR⁵R⁷ or NR⁴CO₂R⁵;

R³ is selected from the group consisting of H, halo, -CN, hydroxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, -NR⁴R⁶, -C₁₋₆alkylNR⁴R⁶, -C₁₋₆alkylOR⁶, CO₂R⁶, O₂CR⁶, COR⁶, CON⁴R⁶, NR⁴CO₂R⁶, NR⁴SO₂R⁶, NR⁴COR⁶, OCONR⁴R⁶, and NR⁴CONR⁵R⁶;

optionally and independently substituted with 1 to 3 substituents selected from the group consisting of -CN, hydroxy, halo, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, CO₂C₁₋₄ alkyl, phenyl or naphthyl; or

R³ is morpholinyl, thiomorpholinyl, piperadiny, piperazinyl, phenyl, pyridyl, pyrimidinyl, triazinyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl,

USSN 10/800,241

CT-2774 NP

pyrrolidinyl, dihydroimidazolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl and indazolyl, independently and optionally substituted with 1 to 4 substituents selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, -OR⁴, halo, C₁₋₄ haloalkyl, -CN, SH, -S(O)₂R⁵, -COR⁴, -CO₂R⁴, -OC(O)R⁵, -N(COR⁴)₂, -NR⁴R⁷ and -CONR⁴R⁷, -NR⁴COR⁵, NR⁴SO₂R⁵, NR⁴CONR⁵R⁷ or NR⁴CO₂R⁵;

Ar is selected from the group consisting of phenyl, indanyl, indenyl, pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, pyrrolidinyl, dihydroimidazolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl, indazolyl, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, independently and optionally substituted with 1 to 4 substituents selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, -OR⁴, halo, C₁₋₄ haloalkyl, -CN, -NO₂, SH, -S(O)₂R⁵, -COR⁴, -CO₂R⁴, -OC(O)R⁵, -N(COR⁴)₂, -NR⁴R⁷ and -CONR⁴R⁷, -NR⁴COR⁵, NR⁴SO₂R⁵, NR⁴CONR⁵R⁷, and NR⁴CO₂R⁵;

R⁴, R⁵ and R⁷ are independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-C₃₋₆ alkyl, C₁₋₂ alkoxy-C₁₋₄ alkyl and C₁₋₄ haloalkyl; and

USSN 10/800,241

CT-2774 NP

R^6 is selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-6} alkyl, C_{1-2} alkoxy- C_{1-2} alkyl, C_{1-4} haloalkyl, phenyl and C_{1-6} alkyl-phenyl.

2. (original) A compound according to claim 1 wherein B is CH.
3. (original) A compound according to claim 1 wherein B is CH and D is CH_2 .
4. (original) A compound according to claim 1 wherein B is CH and D is NH.
5. (original) A compound according to claim 1 wherein R^1 is C_{1-4} alkyl.
6. (original) A compound according to claim 1 wherein R^2 is H or substituted or unsubstituted C_{1-6} alkyl, morpholinyl, piperazinyl or phenyl.
7. (original) A compound according to claim 1 wherein R^3 is H, halo, CN or hydroxy, substituted or unsubstituted C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, $-NR^4R^6$ or O_2CR^6 .
8. (original) A compound according to claim 1 wherein R^3 is pyrimidinyl and pyridinyl.
9. (original) A compound according to claim 1 wherein Ar is phenyl, pyridyl, pyrimidinyl, imidazolyl, thiazolyl, pyrrolidinyl, dihydroimidazolyl optionally substituted with 1 to 4 substituents selected from the group consisting of H, C_{1-6} alkyl, $-OR^4$, halo, C_{1-4} haloalkyl,

USSN 10/800,241

CT-2774 NP

-CN, -NO₂ or -CO₂R⁴.

10. (original) A compound according to claim 1 wherein R⁴, R⁵ and R⁷ are independently H or C₁₋₆ alkyl.

11. (original) A compound according to claim 1 wherein R⁶ is H.

12. (original) A compound according to claim 1 wherein R¹ is C₁₋₄ alkyl; R² is H or substituted or unsubstituted C₁₋₆alkyl, morpholinyl, piperazinyl or phenyl; R³ is H, halo, CN or hydroxy, substituted or unsubstituted C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, -NR⁴R⁶ or O₂CR⁶; Ar is phenyl, pyridyl, pyrimidinyl, imidazolyl, thiazolyl, pyrrolidinyl, dihydroimidazolyl optionally substituted with 1 to 4 substituents selected from the group consisting of H, C₁₋₆ alkyl, -OR⁴, halo, C₁₋₄ haloalkyl, -CN, -NO₂ or -CO₂R⁴; R⁴, R⁵ and R⁷ are independently H or C₁₋₆ alkyl; and R⁶ is H.

13. (original) A compound according to claim 1 wherein B is CH; R¹ is C₁₋₄ alkyl; R² is H or substituted or unsubstituted C₁₋₆alkyl, morpholinyl, piperazinyl or phenyl; R³ is H, halo, CN or hydroxy, substituted or unsubstituted C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, -NR⁴R⁶ or O₂CR⁶; Ar is phenyl, pyridyl, pyrimidinyl, imidazolyl, thiazolyl, pyrrolidinyl, dihydroimidazolyl optionally substituted with 1 to 4 substituents selected from the group consisting of H, C₁₋₆ alkyl, -OR⁴, halo, C₁₋₄ haloalkyl, -CN, -NO₂ or -CO₂R⁴; R⁴, R⁵ and R⁷ are independently H or C₁₋₆ alkyl; and R⁶ is H.

14. (original) [5-(4-Methoxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; 4-[2-Methyl-4-(2,4,6-

USSN 10/800,241

CT-2774 NP

trimethylphenylamino)-pyrimidine-5-sulfonyl]-phenol; Acetic acid 4-[2-methyl-4-(2,4,6-trimethylphenylamino)-pyrimidine-5-sulfonyl]-phenyl ester; [5-(4-Benzyloxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [5-(4-Benzyloxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(4-methoxy-2-methylphenyl)-amine; [5-(4-Benzyloxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(6-methoxy-2-methylpyridin-3-yl)-amine; [5-(3-Benzyloxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [5-(3-Benzyloxybenzenesulfonyl)-2-methoxypyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; 5-(3-Benzyloxybenzenesulfonyl)-N²,N²-dimethyl-N⁴-(2,4,6-trimethylphenyl)-pyrimidine-2,4-diamine; {5-[4-(2-Methoxybenzyloxy)-benzenesulfonyl]-2-methylpyrimidin-4-yl}-(2,4,6-trimethylphenyl)-amine; {5-[4-(3,5-Dimethoxybenzyloxy)-benzenesulfonyl]-2-methylpyrimidin-4-yl}-(2,4,6-trimethylphenyl)-amine; [5-(4-Benzyloxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4-dimethoxyphenyl)-amine; 5-(4-Methoxyoxybenzenesulfonyl)-2-methyl-4-(2,4,6-trimethylbenzyl)-pyrimidine; 5-(4-Benzyloxybenzenesulfonyl)-2-methyl-4-(2,4,6-trimethylbenzyl)-pyrimidine; [5-(4-Fluorobenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-morpholin-4-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; {2-Methyl-5-[4-(4-methylpiperazin-1-yl)-benzenesulfonyl]-pyrimidin-4-yl}-(2,4,6-trimethylphenyl)-amine; [5-(4-Imidazol-1-yl-benzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyrrolidin-1-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [5-(4-Benzylaminobenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; {5-[4-(Benzylmethylamino)-benzenesulfonyl]-2-methylpyrimidin-4-yl}-(2,4,6-trimethylphenyl)-amine; 4-[2-Methyl-4-(2,4,6-trimethylphenylamino)-pyrimidine-5-sulfonyl]-benzonitrile; [2-

USSN 10/800,241

CT-2774 NP

Methyl-5-(toluene-4-sulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyrimidin-5-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyrimidin-2-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyridin-4-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyridin-2-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyridin-3-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; {5-[4-(4,5-Dihydro-1H-imidazol-2-yl)-benzenesulfonyl]-2-methyl-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; or {5-[4-(1H-Imidazol-2-yl)-benzenesulfonyl]-2-methyl-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine or pharmaceutically acceptable salts or solvates thereof.

15. (currently amended) A pharmaceutical composition comprising ~~of a~~ compound according to claim 1 and a pharmaceutically acceptable carrier.

16. (currently amended) A method of treating depression or anxiety comprising the administration of a compound of claim 15.